EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid

Juliano Timm iD, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A Witney, Sylvia A D Rofael iD, Stella Fabiane iD, Morounfolu Olugbosi, Timothy D McHugh, Eugene Sun

PLOS Global Public Health · 18.10.2023 · 3 (10) · e0002283

DOI: 10.1371/journal.pgph.0002283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Global Public Health, online erschienen am 18.10.2023. Verfasst von Juliano Timm und 9 weiteren Autor:innen. Beteiligte Einrichtung: TB Alliance, New York City, New York, United States of America. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Foreign Affairs and Trade, Australian Government, Bill and Melinda Gates Foundation, KfW Entwicklungsbank.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the global prevalence of resistance to these drugs and the impact of resistance on treatment outcomes. Mycobacterium tuberculosis (MTB) phenotypic drug susceptibility and whole-genome sequence (WGS) data, as well as patient profiles from 4 pretomanid-containing trials–STAND, Nix-TB, ZeNix and SimpliciTB–were used to investigate the rates of baseline resistance (BR) and acquired resistance (AR) to BPaL drugs, as well as their genetic basis, risk factors and impact on treatment outcomes. Data from >1,000 TB patients enrolled from 2015 to 2020 in 12 countries was assessed. We identified 2 (0.3%) participants with linezolid BR. Pretomanid BR was also rare, with similar rates across TB drug resistance types (0–2.1%). In contrast, bedaquiline BR was more prevalent among participants with highly resistant TB or longer prior treatment histories than those with newly diagnosed disease (5.2–6.3% vs. 0–0.3%). Bedaquiline BR was a risk factor for bacteriological failure or relapse in Nix-TB/ZeNix; 3/12 (25%, 95% CI 5–57%) participants with vs. 6/185 (3.2%, 1.2–6.9%) without bedaquiline BR. Across trials, we observed no linezolid AR, and only 3 cases of bedaquiline AR, including 2 participants with poor adherence. Overall, pretomanid AR was also rare, except in ZeNix patients with bedaquiline BR. WGS analyses revealed novel mutations in canonical resistant genes and, in 7 MTB isolates, the genetic determinants could not be identified. The overall low rates of BR to linezolid and pretomanid, and to a lesser extent to bedaquiline, observed in the pretomanid trials are in support of the worldwide implementation of BPaL-based regimens. Similarly, the overall low AR rates observed suggest BPaL drugs are better protected in the regimens trialed here than in other regimens combining bedaquiline with more, but less effective drugs.

Autor:innen und Institutionen

  • TB Alliance, New York City, New York, United States of America.
  • Centre for Clinical Microbiology, University College London, Royal Free Campus, London, United Kingdom.
  • Institute of Infection and Immunity, St George's, University of London, London, United Kingdom.
  • Faculty of Pharmacy, University of Alexandria, Alexandria, Egypt.
  • MRC Clinical Trials Unit at University College London, London, United Kingdom.
  • TB Alliance, Pretoria, South Africa.

ORCID-Profile: Juliano Timm, Sylvia A D Rofael, Stella Fabiane

Förderung

  • Department of Foreign Affairs and Trade, Australian Government
  • Bill and Melinda Gates Foundation
  • KfW Entwicklungsbank
  • Irish Aid
  • Netherlands Ministry of Foreign Affairs
  • United States Agency for International Development

Zitieren

APA

Timm, J., Bateson, A., Solanki, P., Paleckyte, A., Witney, A. A., Rofael, S. A. D., Fabiane, S., Olugbosi, M., McHugh, T. D., & Sun, E. (2023). Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Global Public Health, 3(10), e0002283. https://doi.org/10.1371/journal.pgph.0002283

Vancouver

Timm J, Bateson A, Solanki P, Paleckyte A, Witney AA, Rofael SAD, et al. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Global Public Health. 2023;3(10):e0002283. doi:10.1371/journal.pgph.0002283

BibTeX
@article{Timm2023,
  author = {Timm, Juliano and Bateson, Anna and Solanki, Priya and Paleckyte, Ana and Witney, Adam A and Rofael, Sylvia A D and Fabiane, Stella and Olugbosi, Morounfolu and McHugh, Timothy D and Sun, Eugene},
  title = {Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid},
  journal = {PLOS Global Public Health},
  year = {2023},
  volume = {3},
  number = {10},
  pages = {e0002283},
  doi = {10.1371/journal.pgph.0002283}
}
Kostenlos starten →